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In the ﬁrst trimester the extravillous cytotrophoblast cells occlude the uterine spiral arterioles creating a low oxygen environment early in
pregnancy, which is essential for pregnancy success. Paradoxically, shallow trophoblast invasion and defective vascular remodelling of the
uterine spiral arteries in the ﬁrst trimester may result in impaired placental perfusion and chronic placental ischemia and hypoxia later in
gestation leading to adverse pregnancy outcomes. The hypoxia inducible factors (HIFs) are key mediators of the response to low
oxygen. We aimed to elucidate mechanisms of regulation of HIFs and the role these may play in the control of placental differentiation,
growth and function in both normal and pathological pregnancies. The Pubmed database was consulted for identiﬁcation of the most relevant
published articles. Search terms used were oxygen, placenta, trophoblast, pregnancy, HIF and hypoxia. The HIFs are able to function through-
out all aspects of normal and abnormal placental differentiation, growth and function; during the ﬁrst trimester (physiologically low oxygen),
during mid-late gestation (where there is adequate supply of blood and oxygen to the placenta) and in pathological pregnancies complicated
by placental hypoxia/ischemia. During normal pregnancy HIFs may respond to complex alterations in oxygen, hormones, cytokines and
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Advanced Access publication on November 19, 2009 doi:10.1093/humupd/dmp046growth factors to regulate placental invasion, differentiation, transport and vascularization. In the ever-changing environment created during
pregnancy, the HIFs appear to act as key mediators of placental development and function and thereby are likely to be important contribu-
tors to both normal and adverse pregnancy outcomes.
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Introduction
Placentation requires the complex regulation of trophoblast prolifer-
ation, differentiation and invasion. This enables the trophoblasts to
breach the uterine luminal epithelium and colonize the endometrium
and its vasculature in order to sequester a blood supply for the devel-
oping placenta. Impaired placental invasion, development and function
have been implicated in several complications of pregnancy, such as
unexplained miscarriage (Khong et al., 1987), pre-eclampsia, intrauter-
ine growth restriction (IUGR) (Khong et al., 1986), placental abruption
(Dommisse and Tiltman, 1992), pre-term labour with intact mem-
branes (Kim et al., 2003), premature rupture of the membranes
(Kim et al., 2002) and stillbirth (Smith et al., 2004).
In humans, endovascular cytotrophoblasts (CTBs) invade and
initially plug the uterine spiral arterioles, so there is little to no
maternal blood ﬂow to the intervillous space (IVS). Paradoxically,
despite oxygen being essential for late gestation placental function
and fetal growth, the early placenta and embryo differentiate in a rela-
tively low oxygen environment. However, at about 11 weeks of ges-
tation the arteriole plugs are displaced and maternal blood ﬂow
commences (Burton et al., 1999). Extravillous CTBs (EVTs) replace
the maternal endothelium and the spiral arterioles are remodelled,
dramatically increasing in diameter and compliance and are no
longer responsive to vasoactive molecules in the maternal circulation.
This and expansion of the uterine vascular tree, permit the 12-fold
increase in uterine blood ﬂow that occurs from the non-pregnant
state to provide for the demands of the growing fetus later in gestation
(Martin, 1965). However, if trophoblast differentiation, invasion and/
or vascular remodelling are impaired, pregnancy complications can
occur. In pre-eclampsia and some miscarriages, for example, insufﬁ-
cient trophoblast invasion and vascular remodelling in the ﬁrst trime-
ster paradoxically promote premature blood ﬂow into the IVS
leading to reduced maternal blood ﬂow to the placenta later in preg-
nancy (Khong et al., 1987; Rinkenberger et al., 1997; Zhou et al., 1998;
Jauniaux et al., 2003a, b). Hypoxia is therefore implicated as a key reg-
ulator of placental morphogenesis and function. In normal pregnancy,
a low oxygen environment in the placenta is physiological and necess-
ary in the ﬁrst trimester but when it occurs later in gestation it is
pathological and associated with common complications of pregnancy.
Hypoxia inducible factors (HIFs) are key regulators of placental vas-
cularization and invasion as well as trophoblast differentiation and thus
are essential to placental development. It is well known that HIFs
mediate the response to hypoxia, however, it is increasingly apparent
that this regulation is highly complex and, furthermore, that these tran-
scription factors can be regulated by non-hypoxic stimuli. Therefore, in
addition to being potential mediators of the effects of variation in
oxygen supply on placentation, HIFs may also be involved in the regu-
lation of placental development through their interactions with hor-
mones, growth factors and cytokines. This review will examine what
is known about the regulation of placental development and function
by oxygen in both normal and abnormal pregnancies. Furthermore, it
will elucidate mechanisms of acute and prolonged hypoxic regulation,
as well as non-hypoxic regulation, of HIFs and what role these may
play in the control of placental differentiation, growth and function
in both normal and pathological pregnancies. In addition, we will ident-
ify novel interactions which may regulate placental development and
suggest new areas for research.
Methods
Hypoxic regulation of HIF activity in other systems has been extensively
reviewed over many years. Therefore, we provide a brief overview of
this area. An extensive online search of published articles on HIFs and
oxygen in the placenta was undertaken. The Pubmed database was
consulted using combinations of the following search terms: placenta,
trophoblast, pregnancy, HIF, oxygen, hypoxia, non-hypoxic regulation,
angiogenesis, invasion and transport. Where possible we have limited pub-
lications to those involving human placentation. The articles were then
selected based on relevance and quality after discussion between the
authors. References of selected articles were also hand searched for
additional relevant citations. HIF is thought to be regulated at the post-
translational level and thus articles reporting HIF nuclear localization or
DNA binding were given greater weighting. However, as reported in
this review, emerging evidence suggests that HIF may also be regulated
at the transcriptional level and we felt that these reports, although
scarce, were highly novel and worth inclusion, despite the lack of data
on HIF nuclear localization or DNA binding.
Hypoxia inducible factors
HIFs are a family of basic Helix–Loop–Helix transcription factors that
mediate the response to changes in cellular oxygen. HIF-1 is a hetero-
dimer consisting of a HIF-1a subunit bound to the aryl hydrocarbon
nuclear translocator (ARNT), which is also known as HIF-1b (Wang
and Semenza, 1995; Safran and Kaelin, 2003). Following hypoxia-
induced nuclear translocation and dimerization, HIF is able to bind
to the hypoxia response element (HRE) of target genes, which has
the core consensus sequence 50-CGTG-30, in responsive genes (Raja-
kumar and Conrad, 2000). HIFs mediate the expression of a wide
variety of genes that play critical roles in erythropoiesis, angiogenesis,
glucose transport and glycolysis (Wenger and Gassmann, 1999; Safran
and Kaelin, 2003; Rocha, 2007). In mammals, three genes have been
shown to encode HIF-a subunits. The expression of HIF-1a is ubiqui-
tous whereas the expression of its paralogs, HIF-2a (Ema et al., 1997;
Flamme et al., 1997; Tian et al., 1997) and HIF-3a (Gu et al., 1998) are
more restricted (Wenger and Gassmann, 1999; Semenza, 2000;
Daikoku et al., 2003). These data indicate that HIF-1 plays a general
role in homeostasis whereas HIF-2 and HIF-3 may play more special-
ized roles (Wenger and Gassmann, 1999; Semenza, 2000).
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The process of HIF-1a activation has been studied extensively over
the past few years and includes both enhanced protein stability and
transcriptional activity. In well-oxygenated cells, HIF-1a has a half-life
of ,5 min (Wang et al., 1995). Under normoxic conditions the a
subunit is hydroxylated at conserved proline residues (HIF-1a
Pro
564 and Pro
402)( Ivan et al., 2001; Jaakkola et al., 2001; Masson
et al., 2001) contained within a unique oxygen-dependent degradation
domain that critically controls protein stability (Huang et al., 1998;
Srinivas et al., 1999; Huang and Bunn, 2003; Chan et al., 2005). The
enzymes promoting the hydroxylation of these residues are prolyl-4-
hydroxylases (PHDs) of which there are three isoforms, PHD1,
PHD2 and PHD3 (Bruick and McKnight, 2001; Epstein et al., 2001;
Jaakkola et al., 2001). These enzymes have an absolute requirement
for Fe(II) as a cofactor, and molecular oxygen as a co-substrate, but
do not require ATP or NAD (P) (Jaakkola et al., 2001). The require-
ment of the PHD for molecular oxygen means that this reaction can
act as an ‘oxygen sensor’ (Mole et al., 2002).
Once the proline residues of HIF-1a are hydroxylated, the von
Hippel–Lindau (VHL) tumour suppressor gene product (pVHL) is
able to bind (Ivan et al., 2001; Jaakkola et al., 2001; Mole et al.,
2002). pVHL is then able to regulate HIF-1a proteolysis (Maxwell
et al., 1999) by acting as the recognition component of an E3 ubiquitin
protein ligase complex (Lisztwan et al., 1999; Cockman et al., 2000;
Ohh et al., 2000) to mediate polyubiquitination and proteasomal
degradation of HIF-1a under normoxic conditions (Salceda and
Caro, 1997; Huang et al., 1998; Kallio et al., 1999; Tanimoto et al.,
2000).
Regulation of HIF activity
The second means of HIF inhibition during normoxia involves the
hydroxylation of a conserved asparagine residue (Lando et al.,
2002a, b) by factor inhibiting HIF-1 (FIH-1), an asparaginyl hydroxylase
(Mahon et al., 2001; Hewitson et al., 2002; Lando et al., 2002a, b).
Therefore, the hypoxic regulation of HIF requires ﬁrstly the stabiliz-
ation of the HIF-1a subunit and secondly its activation (Minet et al.,
2000). Like other known hydroxylase enzymes, FIH-1 is an Fe(II)-
dependent enzyme that uses molecular oxygen to modify its substrate
(Lando et al., 2002a, b). When oxygen is available, FIH-1 hydroxylates
the a subunit, inhibiting the interaction of HIF-1a and HIF-2a with the
transcriptional co-activators p300/CBP whereas during hypoxia the
non-hydroxylated HIF is free to bind to p300/CBP (Arany et al.,
1996; Dames et al., 2002; Freedman et al., 2002; Lando et al.,
2002a, b).
In addition to FIH-1, other co-factors can impact on HIF function.
Speciﬁcally, p300/CBP interacting transactivator with ED-rich tail 2
(CITED2) is a negative regulator of HIF function. CITED2 actively
competes with HIF-1 for p300/CBP binding (Freedman et al.,
2003). Furthermore, Cited2 expression is activated through a HRE in
its promoter under hypoxic conditions (Bhattacharya et al., 1999)
which suggests a possible negative feedback to HIF transcriptional
activity. CITED2 may play an important role in regulating HIF function
during placentation as CITED2 null mice have impaired trophoblast
differentiation and fetal vascularization of the placenta (Withington
et al., 2006).
Placental oxygenation
There has been much debate in recent years as to whether the term
hypoxia should be used when discussing the oxygen tension in the pla-
centa. Therefore, it is important to outline how we perceive hypoxia
and normoxia during placental development. For the purposes of this
review we have used the term hypoxia only when the oxygen concen-
tration is lower than that to which the placenta is normally exposed.
For example, as will be discussed, the ﬁrst trimester placenta normally
develops in a low oxygen environment and so in this case the oxygen
tension is physiologically normoxic, even though it is lower than that
experienced later in gestation. This is in contrast to, for example, a
term placenta that is experiencing abnormally low oxygen levels and
is therefore classiﬁed as hypoxic or ischemic.
Physiologically low oxygen in early placental
development
In 1987, Hustin and Schaaps reported that maternal blood ﬂow to the
IVS was not fully established until  11–12 weeks of gestation (Hustin
and Schaaps, 1987). The use of Doppler ultrasound during pregnancy
conﬁrmed that there is very little blood ﬂow within the IVS until 11–
12 weeks of gestation (Foidart et al., 1992; Coppens et al., 1996) due
to CTBs initially plugging the maternal spiral arterioles. This is consist-
ent with acid-base and respiratory gas values in the fetal circulation
and placental tissue during the ﬁrst trimester (Jauniaux et al., 2001).
At about 11 weeks of gestation the arteriole plugs are displaced and
blood ﬂow commences (Hustin and Schaaps, 1987; Burton et al.,
1999). The onset of maternal blood ﬂow is progressive, it starts at
the periphery of the placenta and gradually extends towards the
centre (Jauniaux et al., 2003a, b). As a result, the oxygen tension
within the IVS rises from 18 mmHg (2.5%) at 8 weeks to
60 mmHg (8.5%) at 12 weeks (Rodesch et al., 1992; Jauniaux
et al., 2000; Burton and Caniggia, 2001), resulting in a burst of oxi-
dative stress in the placenta, particularly in the syncytiotrophoblast
(STB) (Jauniaux et al., 2000). This switch to a well-oxygenated environ-
ment serves a physiological role in stimulating trophoblast differen-
tiation. However, early onset of maternal blood ﬂow into the IVS
results in a premature increase in placental oxidative stress (Jauniaux
et al., 2003a, b) and is associated with early pregnancy loss (Hustin
et al., 1990; Jauniaux et al., 1994; Jauniaux et al., 2003a, b). This pre-
mature onset of blood ﬂow occurs prior to the establishment of
robust mechanisms to ameliorate oxidative stress since the placenta
only contains low levels of antioxidant enzymes at 8–10 weeks of ges-
tation (Watson et al., 1997; Watson et al., 1998). Therefore, adequate
trophoblast invasion and ‘plugging’ of the uterine arterioles resulting in
a low oxygen environment in early pregnancy are essential for normal
embryonic and placental development.
The above data suggest that trophoblast invasion early in pregnancy
determines placental oxygenation. The question then is what causes
inadequate trophoblast invasion in pathological pregnancies? Indeed
there are many potential regulators of trophoblast invasion including
trophoblast genotype, various growth factors and cytokines and inter-
actions with maternal immune cells. Perhaps to some extent it is also
true that the oxygen environment determines optimal trophoblast
invasion. Oxygen concentration is a major inﬂuence on the balance
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gestation human placentas.
Culturing 5–8-week-old placental villous explants in a low oxygen
environment (2 or 3% O2) stimulates EVT outgrowth associated
with increased trophoblast proliferation compared with explants in a
well-oxygenated environment (20% O2)( Genbacev et al., 1997;
Caniggia et al., 2000a, b). It has therefore been proposed that early
in the ﬁrst trimester (prior to 8 weeks) a low oxygen environment
causes CTBs to proliferate but prevents their differentiation along
the invasive pathway (Genbacev et al., 1997; Caniggia et al., 2000a, b;
Caniggia and Winter, 2002). Similar conclusions were drawn from
using villous explants from 8 to 14 weeks gestation cultured at 2–3,
8 or 20% oxygen (Genbacev et al., 1996; Seeho et al., 2008). In con-
trast, culture of placental samples from 8–10, 12–14 to 16–18 weeks
gestation in 3% O2 inhibited EVT invasion, with no change in cell pro-
liferation, and increased apoptosis at 3 and 8% oxygen compared with
20% O2 (Lash et al., 2006). Similarly, culture of 8–12 week villous
explants in 1.5% oxygen resulted in fewer explants producing EVT out-
growths than those in 8% O2 and a decrease in the area of outgrowth
and number of cells that these explants produced (James et al., 2006).
Utilizing a different in vitro technique involving culture of myometrial
spiral arteries with ﬂuorescently labelled EVTs, culture in 3% oxygen
suppressed EVT invasion regardless of the route (interstitial or endo-
vascular) compared with those cultured in 17% oxygen (Crocker et al.,
2005). However, there was more endovascular EVT invasion than
interstitial invasion in 17% oxygen. These studies demonstrate conﬂict-
ing data on the role of oxygen in the regulation of trophoblast function
particularly regarding trophoblast proliferation, apoptosis and invasion.
This may result from differences in media composition, the substrate
the samples are grown on, oxygen levels used in the experiment or
the gestational age of the trophoblast. In the future we would rec-
ommend that at a minimum, researchers include a group exposed
to 5–10% oxygen in all studies. This is physiological for the placenta
from 10 to 12 weeks onwards and will make results from different
studies easier to interpret. Having only a control group exposed to
20% oxygen, which although a standard culture condition, is actually
hyperoxic, and comparing this to a low oxygen tension, such as 2%,
is only relevant when comparing results with the literature and
makes data much more difﬁcult to interpret and relate to the in vivo
situation.
Furthermore, some studies suggest that culture of HTR-8/SVneo
cells (a human ﬁrst trimester cytotrophoblast cell line) in low (1%)
oxygen conditions promotes invasion of these cells when compared
with culture under standard conditions (20% oxygen) (Graham
et al., 1998). In contrast, there has also been a report that culture
of HTR-8/SVneo cells in 2% oxygen decreases trophoblast invasion
and increases cell proliferation compared with those cultured in 20%
oxygen (Kilburn et al., 2000). In a similar study, the invasiveness of
HTR-8/SVneo cells was increased after 24 h but inhibited by 72 h in
culture (Lash et al., 2007). The presence of serum, the addition of
plasminogen or other factors, the reduced oxygen levels, or the use
of a different invasion assay in the Graham et al.( 1998) study may
account for the different results observed. Microarray and real-time
RT–PCR analyses of HTR-8/SVneo cells exposed to either 20 or
1% oxygen have revealed several genes that encode proteins involved
in cell migration, angiogenesis and apoptosis, as well as anti-invasive
factors which are up-regulated in low oxygen (Koklanaris et al.,
2006), suggesting that a low oxygen environment may ‘ﬁne-tune’ tro-
phoblast differentiation.
Importantly, it is difﬁcult to relate these in vitro observations to the
situation that occurs in vivo, especially when there is such an array of
conﬂicting evidence in the literature. It is clear that in vivo, invading tro-
phoblast cells are exposed to an oxygen gradient as they migrate from
the trophoblast cell column into the maternal decidua. Invading CTBs
respond to this increased oxygen availability by altering the expression
of various cell adhesion molecules and proteases, promoting further
migration. We suggest that future research efforts are directed
toward assessing whether these current in vitro models truly reﬂect
the environment in vivo, by matching gestational age and oxygen con-
centration as much as possible. Additionally, a much more detailed
characterization of placental development as it occurs in vivo is
required (including trophoblast differentiation, invasion, proliferation
and vasculogenesis) as well as of the molecules involved in the regu-
lation of these events and their interaction (e.g. growth factors, cyto-
kines, oxygen levels). Of course this has proven difﬁcult, since there is
a lack of early gestation samples for which the pregnancy outcome is
known.
Placental hypoxia late in pregnancy
Insufﬁcient trophoblast invasion and defective vascular remodelling of
the uterine spiral arteries in the ﬁrst trimester can lead to increased
rate of blood ﬂow, which damages the villous architecture, and an
increased risk of spontaneous vasoconstriction and ischemia-
reperfusion injury resulting in oxidative stress (Burton et al., 2009).
This causes impaired placental perfusion and hence has been
assumed to result in chronic placental ischemia and hypoxia later in
gestation, which is detrimental to pregnancy success and may lead
to pre-eclampsia and/or IUGR, and in some cases will result in
preterm delivery (Chaddha et al., 2004; Viero et al., 2004). Although
the preeclamptic and IUGR placentas are thought to be hypoxic, to
date there have been no direct measurements to support this assump-
tion. Interestingly, in pregnancies at high altitude, where placental
hypoxia has been considered to be exacerbated, infant birthweight
is decreased, primarily due to a slowing of fetal growth in the third tri-
mester (reviewed in Zamudio, 2003; Moore et al., 2004), and these
pregnancies have an increased incidence of pre-eclampsia. Sub-
sequently, there is also an increased incidence of perinatal and infant
mortality and morbidity in pregnancies at high altitude. Importantly,
placentas from uncomplicated pregnancies at high altitude show no
indication of signiﬁcant hypoxic stress at term compared with placen-
tas from pregnancies at low altitude and appear to have successfully
adapted to the lower oxygen atmosphere (Tissot van Patot et al.,
2004; Zamudio et al., 2007a, b). It is unclear then whether these pla-
centas can actually be considered hypoxic and it will be important in
future to determine why some placentas apparently adapt to the
hypoxic environment and others do not.
Thus, oxygen appears to play a critical role in the development of
pregnancy complications and is a key mediator of placental develop-
ment and function. During pregnancy a low oxygen environment can
result in different outcomes depending on the timing of exposure in
pregnancy, the severity of the hypoxic exposure and the duration.
The exact mechanism by which trophoblasts sense oxygen tension
is currently unclear. However, several potential pathways have been
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factors, of which the HIF family is the best characterized in
trophoblasts.
Expression and function of HIFs
in the placenta
Both HIF-1a and HIF-2a proteins are constitutively expressed in the
human placenta. In the ﬁrst trimester, HIF-1a and -2a have been loca-
lized in the STB, villous CTB and fetoplacental vascular endothelium
(Rajakumar and Conrad, 2000; Genbacev et al., 2001), consistent
with the low oxygen environment of the placenta during the ﬁrst tri-
mester of pregnancy, but their abundance decreases signiﬁcantly
with gestational age (Caniggia et al., 2000a, b; Rajakumar and
Conrad, 2000; Caniggia and Winter, 2002). More speciﬁcally Ietta
et al. (2006) have described in detail the dynamic expression of HIF
and HIF regulators during placental development. HIF-1a and VHL
mRNA and protein are present throughout gestation, with levels
peaking at 7–10 weeks of gestation, when the oxygen tension is
low, and declining thereafter (Ietta et al., 2006).
During early pregnancy, HIF-1a can be immunolocalized to CTBs
and EVTs while VHL is present in STB. By 10–12 weeks, HIF-1a dis-
appears, coinciding with an increase in expression of VHL in the CTB
and an increase in VHL:HIF-1a binding throughout the placenta (Ietta
et al., 2006). The expression of ARNT and HIF-2a mRNA and protein
are present and stable throughout gestation (Ietta et al., 2006). The
PHD enzymes (PHD1, 2, 3) are also dynamically expressed in an
oxygen dependent fashion, peaking at 10–12 weeks gestation (Ietta
et al., 2006). Previous reports by others have found slightly different
results. In 2000, Rajakumar et al. reported that the levels of Hif-1a
mRNA in the placenta do not change across gestation, while Hif-2a
mRNA abundance increases as gestation proceeds (Rajakumar and
Conrad, 2000). However, it would be most pertinent to quantify
HIF-1a and HIF-2a proteins and determine their cytoplasmic versus
nuclear localization and DNA binding in the placenta across gestation
in order to understand HIF-1 activity.
In a preliminary report examining pregnancies at high altitude, HIF-1
DNA binding (measured by enzyme-linked immunosorbent assay) and
HIF-associated proteins were unchanged compared with placentae
from low altitude pregnancies (Tissot van Patot et al., 2004), leading
to the conclusion that there was placental adaption to the hypoxic
environment. However, in a more recent and comprehensive study,
HIF-1a and VHL mRNA and protein levels were signiﬁcantly increased
in placentae from high altitude pregnancies, whereas Hif-2a and Arnt
levels are unchanged (Zamudio et al., 2007a, b). Similarly, HIF-1a
and HIF-2a are over-expressed in the villous placenta of women
with pre-eclampsia compared with normal term pregnancies
(Rajakumar et al., 2001; Rajakumar et al., 2004), with the expression
of HIF-1a in villous and extravillous trophoblast cells being similar to
the expression in trophoblasts prior to exposure to increased
oxygen in ﬁrst trimester (Caniggia and Winter, 2002). Oxygen-
dependent down-regulation of HIF-1a and -2a protein is impaired
in pre-eclampsia (Rajakumar et al., 2003), likely a result of both
increased formation and decreased degradation owing to proteosome
dysfunction (Rajakumar et al., 2008). Consistent with this, others have
reported enhanced placental expression of HIF target genes, including
Vegf, in pregnancies complicated by pre-eclampsia and IUGR (Helske
et al., 2001), which maybe suggestive of a vasculo-adaptative response
to chronic hypoxia at the fetoplacental–maternal interface. Both
HIF-1a and HIF-2a are therefore in an ideal position to regulate pla-
cental development throughout gestation in both normal and patho-
logical pregnancies.
Differential regulation of HIF-1a
and HIF-2a in acute versus
prolonged hypoxia
The degradation of the HIF-a protein and its stabilization under
hypoxia has been the focus of much research in the last 10 years. In
particular, it is apparent that HIF-1a and HIF-2a may respond differ-
ently depending on the length and severity of hypoxic exposure.
HIF-2a is expressed to a higher degree than HIF-1a in a number of
endothelial, ﬁbroblast-like and epithelial cell lines in normoxic con-
ditions (Wiesener et al., 1998). In addition, HIF-2a is increased to a
greater extent than HIF-1a following exposure to mild hypoxia (5%
O2)( Wiesener et al., 1998; Holmquist-Mengelbier et al., 2006). It
has now been proposed that HIF-1a stabilization in hypoxia (1%
O2) is an acute response, which is diminished under prolonged
periods of low oxygen exposure (reviewed in Lofstedt et al., 2007).
Conversely, HIF-2a protein levels are increased under mild hypoxia
(5% O2) and continue to increase with time, thereby playing an impor-
tant role in mediating effects on gene expression under conditions of
prolonged exposure to low oxygen. In addition, it is likely that a differ-
ent set of HIF targets are up-regulated in response to acute versus
prolonged hypoxia but this phenomenon is yet to be examined in
the placenta.
Differential regulation of the mRNA for the a subunits has been
reported in response to acute and chronic hypoxia. For instance, in
rats, Hif-3a, but not Hif-1a or Hif-2a, mRNA levels increase in the
cerebral cortex, hippocampus, lung, heart, liver and kidney after 2 h
of in vivo hypoxic exposure but no change was seen within 30 min
(Heidbreder et al., 2003). In contrast, a previous study had shown
that Hif-1a mRNA in rat and mouse brain, kidney and lung was
up-regulated within 30 min of hypoxia treatment in vivo, but returned
to baseline after 4 h (Wiener et al., 1996). Similarly, Wang et al.
showed that hypoxia induces the expression of Hif-1 mRNA in vitro
but this is diminished by longer periods of hypoxia (Wang et al.,
1995; Uchida et al., 2004). These studies suggest that Hif-1a mRNA
is transiently increased in response to hypoxic stimuli. Consistent
with this, others have reported unaltered Hif-1a mRNA levels in
mice in response to 4 h of hypoxia in vivo (Wenger et al., 1996).
In 1999, a naturally occurring antisense transcript of HIF-1a (asHif-1a)
wasdiscoveredinhumanrenalcancer(Thrash-BinghamandTartof,1999).
Morerecently,asHif-1awasidentiﬁedinthekidney,liver,testis,brain,lung,
spleen, heart and skeletal muscle of rodents (Rossignol et al., 2004)a n d
speciﬁcally in the mouse decidua and trophoblasts early in gestation
(Pringle et al., 2007). It has been suggested that asHIF-1a exposes AU
rich elements in the 30untranslated region of Hif-1a mRNA which
decreases the stability of Hif-1a mRNA (Fig. 1), impairing HIF-1a
protein translation and expression (Rossignol et al., 2002). Conversely,
Hif-2a mRNA is not destabilized by asHIF-1a owing to the lack of AU
rich elements (Uchida et al., 2004). In fact, Hif-2a transcription can
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2002).SinceasHif-1acontainsaputativeHREitisassumedthatbothHIF-1
andHIF-2areinvolvedintheregulationofasHif-1aexpressionthuscreat-
ing a negative feedback loop of HIF regulation under prolonged hypoxia
(Fig. 1)( Rossignol et al., 2002; Uchida et al., 2004).
In the placenta, some evidence of differing responses to acute
versus prolonged hypoxic exposure can be found but to date no
studies have examined this directly. Human placental villous explants
from 5 to 8 weeks gestation, cultured at 3% oxygen demonstrated sig-
niﬁcantly greater mRNA expression of Hif-1a when compared with
explants cultured at 20% oxygen, after 24 h of culture (Caniggia
et al., 2000a, b). First trimester or term villous explants exposed to
2% oxygen for 3–24 h showed increases in HIF-1a and HIF-2a
protein expression, with no change in their mRNA levels, and
increased HIF-1 DNA binding activity (Rajakumar and Conrad,
2000). However, in cultured 6–8 week placenta it was HIF-2a
protein that dramatically increased following 48 h exposure to 2%
oxygen, whereas HIF-1a levels were the same in those explants cul-
tured under hypoxic and normoxic conditions (Genbacev et al.,
2001). These in vitro studies have yielded inconclusive results, which
may result from the use of different oxygen tensions, culture con-
ditions or duration of exposure.
In the future it will be important to investigate the effect of different
oxygen concentrations and prolonged versus acute hypoxic exposure
on HIF mRNA and protein and their targets throughout placental
development in more detail. In addition, asHIF-1a expression and
localization in the human placenta has yet to be elucidated. In the
mouse, we have found that culture of early trophoblasts in 1%
oxygen for 3 days signiﬁcantly decreases Hif-2amRNA abundance
whereas Hif-1amRNA levels remain unchanged (Pringle et al.,
2007). Furthermore, our data suggest that the differential effects on
Hif-1 and 2a mRNA levels may be mediated by an increase in
asHif-1a mRNA in trophoblasts cultured in 1% oxygen. Research in
this area may be of critical importance when considering the role of
HIFs in prolonged hypoxic exposure of the placenta, such as occurs
in pre-eclampsia and pregnancy at high altitude.
Non-hypoxic induction
of HIF-1a
HIF-1a can also be induced by factors other than hypoxia, including
hormones, cytokines and growth factors (Table I), many of which
are expressed in the placenta or are increased in the maternal
Figure 1 Mechanism of HIF regulation under acute and prolonged hypoxia. Under acute hypoxia, HIF-1a and HIF-2a are stabilized and can induce
the transcription of their target genes. Following exposure to prolonged hypoxia, HIF-1a and HIF-2a can up-regulate the expression of the antisense
transcript of HIF-1a (asHIF-1a) which, in turn, destabilizes HIF-1a mRNA thereby reducing HIF-1a protein levels and HIF-1a mediated gene tran-
scription. Therefore under prolonged hypoxia HIF-2a mediated transcription is more abundant. HRE: hypoxia response element.
420 Pringle et al.circulation during pregnancy. Indeed, HIF-1a protein is up-regulated in
a well-oxygenated environment (20% oxygen) during Matrigel
induced endovascular differentiation in a human EVT cell line
(Fukushima et al., 2008). The mechanisms, however, are unknown.
Hif-1a mRNA can be regulated by progesterone in the mouse
uterus whereas estrogen has the ability to regulate Hif-2a mRNA
(Daikoku et al., 2003). In sheep, progesterone treatment increases
HIF-1a and HIF-2a protein but not mRNA in endometrial luminal
and superﬁcial glandular epithelium (Song et al., 2008). Similarly,
exposure of colon cancer cells to prostaglandin E2 (PGE2) induces
the expression of vascular endothelial growth factor (VEGF) via
increased HIF-1a (Fukuda et al., 2003). HIF-1a protein levels in vascu-
lar smooth muscle cells are strongly increased in normal oxygen
conditions when cells are stimulated with angiotensin II (Ang II),
thrombin, platelet derived growth factor (PDGF) or Transforming
Growth Factor-b1 (TGF-b1) (Richard et al., 2000; Gorlach et al.,
2001; Page et al., 2002). More recently, it was found that TGF-b1
decreases mRNA and protein levels of PHD2, through the Smad sig-
nalling pathway, thereby inhibiting the degradation of HIF-1a
(McMahon et al., 2006). Other non-hypoxic inducers of HIF-1a
include Endothelin 1 (Spinella et al., 2002), epidermal growth factor
(Jiang et al., 2001), Rho A which regulates actin stress ﬁbres
(Hayashi et al., 2005) and even cyclical mechanical stretch (Chang
et al., 2003).
Of particular interest is a recent study demonstrating that in ﬁrst tri-
mester placental villous explants Ang II mimics the effects of hypoxia
.............................................................................................................................................................................................
Table I Non-hypoxic regulators of HIFs.
Non-hypoxic
stimuli
Action Proposed
mechanism
Found in
placenta (Yes/
No)
HIF target
gene (Yes/
No)
References
Progesterone Increased Hif-1a mRNA,
or HIF-1a and HIF-2a
protein
? Yes No Daikoku et al. (2003), Song et al. (2008)
Estrogen Increased Hif-2a mRNA ? Yes No Daikoku et al. (2003)
Prostaglandin E2 Increased HIF-1a
protein
ERK, AKT, C-SRC
tyrosine kinase activity
Yes No Fukuda et al. (2003)
Angiotensin II Increased HIF-1a
mRNA and protein
AT1R, PKC, ROS
activation
Yes No Richard et al. (2000), Page et al. (2002),
Araki-Taguchi et al. (2008)
Thrombin Increased HIF-1a
mRNA, protein and
activity
AT1R, PKC, ROS
activation
Yes No Richard et al. (2000), Gorlach et al.
(2001), Page et al. (2002)
Platelet derived
growth factor
Increased HIF-1a
protein and activity
Via ROS activation Yes No Richard et al. (2000), Gorlach et al.
(2001)
Transforming
growth factor-b1
Increased HIF-1a
protein via inhibiting
HIF-1a degradation
Decreased VHL mRNA
and protein via Smad
pathway
Yes Yes Gorlach et al. (2001), McMahon et al.
(2006)
Endothelin-1 Increased HIF-1a
protein
? Yes Yes Spinella et al. (2002)
Epidermal Growth
Factor
Increased HIF-1a
protein
Via PI3K Yes No Jiang et al. (2001)
RhoA Increased HIF-1a
protein
? Yes No Hayashi et al. (2005)
Mechanical stretch Increased HIF-1a
mRNA and protein
Via p42/p44 MAPK
pathway
Chang et al. (2003)
Interleukin-1b Increased HIF-1 protein ERK 1/2 activation Yes Yes Hellwig-Burgel et al. (1999), Karmakar
and Das (2002), Qian et al. (2004)
Tumor Necrosis
Factor-a
Increased HIF-1 DNA
binding
Activation of HIF
co-activators, NFkB
pathway
Yes No Zhou and Bondy (1992), Hellwig-Burgel
et al. (1999), Huber et al. (2006)
Insulin Increased Hif-3a mRNA,
HIF-1a and HIF-3a
protein
Via PI3 and MAPK
pathways
Yes No Zelzer et al. (1998), Feldser et al. (1999),
Jiang et al. (2001), Heidbreder et al.
(2003), Treins et al. (2002)
Insulin-like Growth
Factor-I
Increased HIF-1a and
HIF-2a protein
Via PI3 and MAPK
pathways or through
PHD2
Yes No Zelzer et al. (1998), Feldser et al. (1999),
Chavez and LaManna (2002), Richard
et al. (2000)
Insulin-like Growth
Factor-II
Increased HIF-1a
protein, decreased
Hif-2a mRNA
Via Mdm2 and decreased
p53
Yes Yes Feldser et al. (1999), Kwon et al. (2004),
Pringle et al. (2007)
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In addition, Ang II increased EVT outgrowth and the number of cells in
CTB cell columns and increased Ki67 suggesting an increase in prolifer-
ation (Araki-Taguchi et al., 2008). Ang II has also been shown to
increase plasminogen activator inhibitor (PAI)-1 synthesis and
secretion in human trophoblasts through the type 1 angiotensin recep-
tor (AT1R) and is associated with decreased trophoblast invasion (Xia
et al., 2002; Araki-Taguchi et al., 2008). Interestingly, it has been pro-
posed that Ang II and the renin angiotensin system may play a role in
the development of pre-eclampsia. Ang II levels in the placental bed
are signiﬁcantly elevated in women with pre-eclampsia (Anton et al.,
2009), and may act on the placental villi, which display an up-regulation
of AT1Rs (Anton et al., 2008),
Cytokines also regulate HIF in normoxia. For example, interleukin
(IL)-1b and tumour necrosis factor (TNF)-a increased HIF-1 DNA
binding in human hepatoma cells (Hellwig-Burgel et al., 1999). IL-1b
increased HIF-1a nuclear protein, whereas the positive effect of
TNF-a on HIF-1 DNA binding was suggested to result from activation
of HIF co-activator proteins (Hellwig-Burgel et al., 1999). Similarly, a
more recent study found that IL-1b induces HIF-1a-mediated VEGF
secretion in normal human trophoblast cells and this may be a
result of ERK 1/2 activation (Qian et al., 2004). Interestingly, matrix
metalloproteases (MMP-2, MMP-9) and urokinase plasminogen activa-
tor (uPA), which are abundantly expressed by CTBs and degrade the
extracellular matrix (ECM), were also up-regulated by IL-1b in human
trophoblasts (Karmakar and Das, 2002). In contrast, HIF-1a protein
accumulation induced by TNFa requires the NFkB pathway (Zhou
et al., 2003). In addition, TNFa inhibits trophoblast migration
through elevation of PAI-1 in ﬁrst trimester villous explant cultures
(Bauer et al., 2004; Huber et al., 2006) likely by activation of NFkB
(Huber et al., 2006). Indeed a recent review by Redman and
Sargent (2009) emphasizes the role of inﬂammatory stimuli in HIF
accumulation. This may be important in both normal pregnancies,
where a systemic inﬂammatory response is evident, and in pathological
pregnancies, such as pre-eclampsia, where inﬂammation is exagger-
ated. To date there have been few studies on the role of HIF in the
placental inﬂammatory response but research in this area may
provide novel insights in the future.
Although insulin-like growth factor (IGF)-II is known to be a target
gene of HIF-1 (Feldser et al., 1999), insulin, IGF-I and IGF-II are all able
to induce HIF-1a protein expression in various cell lines (Zelzer et al.,
1998; Feldser et al., 1999; Jiang et al., 2001; Chavez and LaManna,
2002; Treins et al., 2002; Thomas and Kim, 2008; Alam et al.,
2009). Similarly, both insulin and 2-deoxy-D-glucose treatment
resulted in a widespread increase in HIF-3a mRNA and protein
(Heidbreder et al., 2007). IGF-I can also induce VEGF expression in
human osteoblast-like cells through transcriptional activation involving
the HIF-2a/ARNT complex (Akeno et al., 2002). However, the mag-
nitude of the increase in HIF protein induced by insulin or IGFs in vitro
is far less than that caused by hypoxia. In contrast, IGF-II treatment of
mouse trophoblasts in vitro has been shown to decrease Hif-2a,
asHif-1a, Glut-1 and Vegf mRNA levels following culture in prolonged
hypoxia, but not in well oxygenated cells (Pringle et al., 2007). This
suggests that the response to growth factors varies depending on
the oxygen availability.
Many, if not all, of the non-hypoxic regulators of HIF protein abun-
dance reported to date are present and active in the placenta
(Table I). To date, the role of HIF in mediating their effects in the pla-
centa has been little studied. As an initial step, it will be important in
the future to identify which of these non-hypoxic regulators of HIF
(outlined in Table I) are playing a similar role in the placenta. From
there we can start to examine the role of non-hypoxic HIF regulation
in placental development and when this may occur. This would be a
novel approach to research on placental HIF and will provide exciting
insights into the regulation of placental development. In addition, it is
important to consider possible interactions between hypoxic and non-
hypoxic HIF regulators and the effects these may have. Importantly, it
will be essential to also examine the role of both hypoxic and non-
hypoxic HIF regulation in pathological pregnancies, such as pre-
eclampsia, and whether these interact.
Regulation of placental
development and function
by HIF target genes
HIF target genes may therefore be regulated by either hypoxic or non-
hypoxic stimuli and many of these genes have critical roles in placental
development and function. Interestingly, some HIF target genes, such
as IGF-II and TGF-b, are also non-hypoxic regulators of HIF (Table I)
whereas others can feed back to regulate HIF in prolonged hypoxia.
Therefore, these molecules may provide novel co-regulatory
responses or feedback pathways in the regulation of placental develop-
ment. Many other HIF target genes have not yet been investigated in
this way but further research may provide interesting insights into the
complexity of interrelationships between HIF and its target genes.
Here, we outline just some of the numerous roles that HIF-regulated
genes have in placental development and how they could interact to
regulate its differentiation, growth and function through HIF depen-
dent or independent mechanisms.
Trophoblast invasion and migration
Hif1a 2/2 Hif2a 2/2 mice display a 17% reduction in trophoblast
invasion compared with wild type placentae (Cowden Dahl et al.,
2005). Several pro- and anti-invasive factors that are expressed by
the trophoblast cells themselves or by the maternal decidua are HIF
target genes. Furthermore, these factors seem to interact in such a
way that they are able to tightly coordinate the extent and timing of
trophoblast invasion and migration.
uPA system
uPA, the uPA receptor (uPAR) and uPA inhibitors play a central role in
trophoblast migration and invasion. EVTs have been shown to exhibit
a highly polarised distribution of uPAR-bound uPA at the invasive front
(Multhaupt et al., 1994). uPA is secreted as an inactive proenzyme
(pro-uPA) which, upon binding to its speciﬁc uPAR on the cell
surface, is cleaved to its active form. Following activation, cell mem-
brane bound uPA can catalyse the conversion of the inactive
zymogen plasminogen, to the active proteinase plasmin (Kjoller
et al., 1997) which can then go on to activate MMPs and directly
degrade certain ECM components required for invasion and remodel-
ling of the maternal decidua. This process is modulated by tissue
inhibitors of matrix metalloproteinases (TIMPs) and PAI-1 which are
predominantly synthesized by the decidua but also by the invading
422 Pringle et al.trophoblasts (Yebra et al., 1996; Floridon et al., 2000). Interestingly,
the uPA:uPAR interaction can stimulate EVT migration independently
of uPA catalytic action, via the mitogen activated protein kinase
(MAPK) pathway and calcium signalling events that require
phosphatidylinositol-3 kinase and phospholipase C (Liu et al., 2003).
Culture of HTR-8/SVneo trophoblasts less than 1% oxygen results
in elevated expression of uPAR at the mRNA and cell surface bound
protein levels and promotes trophoblast invasion (Graham et al.,
1998). However, a more recent study has shown that culture in 3%
oxygen inhibits early gestation EVT invasion, increases uPAR and
PAI-2 expression and decreases uPAR activity (Lash et al., 2006).
Although direct experimental evidence for HIF regulation of uPA in
placenta is currently lacking, PAI-1 mRNA and protein levels have
been shown to increase in HTR-8/SVneo cells in response to
hypoxia via HIF-1a or HIF-2a [determined by small interfering RNA
(siRNA) against HIF-1a and -2a]( Fitzpatrick and Graham, 1998;
Meade et al., 2007) and may provide a mechanism for the control
of trophoblast invasion.
Insulin-like growth factor-II
IGF-II is regulated by HIF (Feldser et al., 1999) among other factors
and is thought to play an important role in placental development.
Maternal circulating concentrations of IGF-II increase during early
pregnancy in humans (Wilson et al., 1982; Gargosky et al., 1990). In
addition, presumed in vivo hypoxia at term has been associated with
increased levels of placental Igf2 mRNA (Trollmann et al., 2007)
whereas placental IGF-II protein is elevated in preeclamptic placenta
(Gratton et al., 2002). Direct evidence for HIF regulation of IGF-II in
the placenta has not yet been reported but warrants further investi-
gation. Indeed, IGF-II has been shown to promote migration of
human EVT cells (Irving and Lala, 1995; Hamilton et al., 1998;
McKinnon et al., 2001), increase proliferation in ﬁrst trimester villous
CTBs in vitro (Hills et al., 2004; Forbes et al., 2008) and decrease
CTB apoptosis (Forbes et al., 2008). IGF-II induced migration of
EVT cells in vitro is thought to be mediated by the IGF2R using a
Gi-coupled receptor and (MAPK) intracellular signalling pathway
(McKinnon et al., 2001).
The bioavailability and biological actions of the IGFs are regulated by
a family of 6 IGF binding proteins (IGFBPs 1-6). Interestingly, IGFBP-1,
-2 and -3 are also HIF regulated genes (Tazuke et al., 1998; Feldser
et al., 1999). In blood, 75% of IGFs circulate as a complex with
IGFBP-3 or IGFBP-5 and the acid-labile subunit, which acts as a reser-
voir (Mohan and Baylink, 2002). The remaining IGFs in the circulation
bind to one of the remaining IGFBPs enabling them to cross the endo-
thelium, increasing their availability to local tissues. Binding of IGFs to
IGFBPs can result in either inhibition or enhancement of IGF actions.
The afﬁnity of IGFBPs for IGFs is higher than that of the receptors for
IGFs, therefore binding of IGFBPs to IGFs prevents interactions with
the IGF receptors (Clemmons, 1998; Baxter, 2000; Mohan and
Baylink, 2002; Rosenzweig, 2004; Duan and Xu, 2005). Conversely,
several studies have also shown that a number of IGFBPs are able
to stimulate IGF actions in a variety of cell types. Indeed, the same
IGFBP can act to enhance or inhibit IGF actions depending on the
cell type, abundance of IGFBP and post-translational modiﬁcations
such as glycosylation or phosphorylation, which result in altered afﬁnity
for IGFs (Baxter, 2000; Mohan and Baylink, 2002; Duan and Xu,
2005). Furthermore, IGF-II can alter the phosphorylation state of
IGFBP-1 at the feto-maternal interface promoting its own actions
(Westwood et al., 1997). Several IGFBPs are also associated with
the cell surface or ECM, reducing their afﬁnity for the IGFs, and
hence can also modulate IGF actions (Clemmons, 1998; Baxter,
2000; Mohan and Baylink, 2002).
Transforming growth factor-b
The TGF-b isoforms are believed to be major factors regulating CTB
behaviour and are commonly thought to inhibit cell proliferation and
invasion (Bischof, 2001). TGFb3 expression is induced by hypoxia
both in vivo and in vitro and is directly regulated by HIF-1 in trophoblast
cells (determined by siRNA knockdown of HIF-1a)( Caniggia et al.,
2000a, b; Schaffer et al., 2003; Nishi et al., 2004). Interestingly, both
HIF-1a and TGF-b3 are overexpressed in preeclamptic placentae
(Nishi et al., 2004). However, during normal pregnancy, the decidua
is the major source of TGF-b. TGF-b1 inhibits EVT invasion via the
RhoA/Rho-associated kinase (ROCK) pathway (Fafet et al., 2008)
by up-regulating integrin expression (Irving and Lala, 1995) and redu-
cing uPA activity in vitro via decreasing the secretion of uPA and
increasing the production and secretion of PAI-1 (Graham, 1997; Fitz-
patrick and Graham, 1998). Similarly, TGF-b1 can up-regulate TIMP-1
and -2, PAI-1 and -2 (Karmakar and Das, 2002) and deposition of
ECM components (Feinberg et al., 1994) and adhesive cell surface
molecules (Meisser et al., 1999; Karmakar and Das, 2004) in human
trophoblasts in vitro. TGF-b1 is also known to inhibit steroidogenesis
in human trophoblasts (Luo et al., 2002) and promotes syncytium for-
mation in isolated ﬁrst trimester trophoblast primary cultures by
increasing surface expression of cadherin-11 (Getsios et al., 1998).
In contrast to this, ﬁrst trimester villous explants, exposed to either
antisense TGF-b3 oligonucleotide or TGF-b3 antibody (but not
those for TGF-b1 or TGF-b2), displayed prominent EVT outgrowth
from the distal end of the villous tip and an increased number of
cells migrating into the surrounding matrix (Caniggia et al., 1999).
TGF-b is secreted in a latent pro-form in complex with a latency
associated peptide (LAP) and has the ability to bind the IGF2 receptor
(IGF2R) (via M6P residues in the LAP) which interacts with the uPAR
on the cell surface (Godar et al., 1999). uPA binding to uPAR allows
uPA to cleave plasminogen into plasmin which can then go on to
cleave the LAP, and active TGF-b1 is released. This provides a
novel interaction between the uPA, IGF-II, TGF-b and HIF systems
whereby, depending on the relative abundance of IGF-II and/or
TGF-b, the uPAR/IGF2R interaction can be utilized to either
promote or inhibit trophoblast migration and invasion. Importantly,
hypoxia-induced HIF regulation of IGF-II, TGF-b, PAI-1, uPAR and
uPA will also impact on this system and ultimately, trophoblast behav-
iour. In addition, non-hypoxic regulation of HIFs by IGF-II and TGF-b
may provide additional feedback pathways.
Placental vascularization
It is thought that the low oxygen environment in the placenta controls
CTB vascular remodelling and acts as a major regulator of placental
angiogenesis. Indeed, Hif1a 2/2 Hif2a 2/2 mice have impaired
placental vascularization (Cowden Dahl et al., 2005). The VEGFs are
key molecules involved in angiogenesis. The VEGF family consists of
VEGF (VEGF-A), VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental
growth factor (PlGF), the latter of which is closely related to
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VEGFR-2 (KDR, called Flk-1 in mice) and VEGFR-3, as well as a
soluble form of Flt-1 (sFlt-1) that is generated by alternative splicing
and lacks transmembrane and cytoplasmic domains (Kendall and
Thomas, 1993). VEGF is thought to act locally via its receptors,
VEGFR-1 and VEGFR-2, to establish the fetoplacental circulation.
VEGF is hypoxia inducible and is a well-known HIF target gene
(Wang and Semenza, 1995). Circulating sFlt-1 binds VEGF and PlGF
with high afﬁnity thereby decreasing their availability for the transmem-
brane receptors VEGFR-1 and VEGFR-2. Although not members of
the VEGF family, the angiopoietins are also involved in placental vascu-
logenesis through their interaction with tyrosine kinase receptor
(Tie-2) and are inﬂuenced by oxygen availability (Zhang et al., 2001).
It appears that rather than solely their concentration at the feto-
maternal interface, the ratio and interaction of VEGF family
members, angiopoietins and growth factors orchestrate the develop-
ment of the placental vasculature and all in all, this is inﬂuenced by
oxygen (Charnock-Jones and Burton, 2000).
PlacentalvillousandextravilloustrophoblastssecretesFlt-1duringpreg-
nancy (Clark et al., 1998) and sFlt-1 levels in the maternal circulation
increase with increasing gestational age (Koga et al., 2003). Interestingly,
sFlt-1mRNAlevelsandsFlt-1secretionintoculturemediaareup-regulated
following exposure to a low oxygen environment in villous explants from
ﬁrst trimester and uncomplicated and preeclamptic pregnancies at term
(Rajakumar et al., 2009). HIF-1a knockdown using antisense oligonucleo-
tides has demonstrated that this up-regulation is mediated by HIF-1a in
ﬁrst trimester villous explants (Nevo et al., 2006). In addition, placental
sFlt-1isup-regulatedinpre-eclampsia,leadingtoincreasedmaternalcircu-
latingconcentrationsofsFlt-1thatprecedesymptomsandfallafterdelivery
(Kogaetal.,2003;Maynardetal.,2003;Rajakumaretal.,2005;Rajakumar
et al., 2007; Rajakumar et al., 2009).
Recently, multiple isoforms of sFlt-1 have been identiﬁed in the cir-
culation of women with pre-eclampsia as well as in uncomplicated
pregnancies (Rajakumar et al., 2009). Vegf and its receptor Flt-1
mRNA levels are also increased in preeclamptic placenta compared
with controls (Tsatsaris et al., 2003; Rajakumar et al., 2004; Rajakumar
et al., 2005; Rajakumar et al., 2007). Conversely, membrane bound
Flt-1 is decreased in the placental bed of patients with pre-eclampsia
(Tsatsaris et al., 2003). Pre-eclampsia is associated with an increase in
total circulating VEGF, but decreased free VEGF and PlGF a result of
increased sFlt-1 (Maynard et al., 2003; Tsatsaris et al., 2003) and
this is thought to contribute to endothelial dysfunction seen in pre-
eclampsia. Indeed, administration of sFlt-1 to pregnant rats induces
hypertension, proteinuria and glomerular endotheliosis (Maynard
et al., 2003). Of considerable interest is the observation that exper-
imental induction of utero-placental insufﬁciency (ischaemia with
restricted transport function) by uterine artery ligation in baboons
resulted in a pre-eclampsia-like syndrome with hypertension and pro-
teinuria and, notably, elevated placental and maternal circulating
monocyteFlt-1 mRNA and increased sFlt-1 protein in plasma (Makris
et al., 2007).
Recently, sFlt-1 was shown to be up-regulated in pregnant mice
lacking catechol-O-methyltransferase (Comt 2/2 mice) (Kanasaki
et al., 2008). COMT generates 2-methoxyoestradiol (2-ME) from
hydroxyoestradiol, a potent inhibitor of angiogenesis (Fotsis et al.,
1994; Mabjeesh et al., 2003). These Comt 2/2 pregnant mice
display a pre-eclampsia-like phenotype, including endothelial damage
in the decidual arteries and renal glomeruli, gestational hypertension
and proteinuria (Kanasaki et al., 2008). Importantly, this
pre-eclampsia-like phenotype is restored by the administration of
2-ME. This is in accordance with human preeclamptic pregnancies
which display decreased levels of 2-ME and COMT (Kanasaki et al.,
2008). Additionally, Comt 2/2 mice display signs of hypoxia (as
determined by hypoxyprobe localization), elevated nuclear HIF-1a
in the placenta and increased circulating sFlt-1, which was prevented
by 2-ME administration. 2-ME is a negative regulator of HIF-1a
(Mabjeesh et al., 2003) and was further shown to suppress
hypoxia-inducedHIF-1aandsFlt-1inHTR-8trophoblastcells(Kanasaki
et al., 2008). This very elegant study by Kanasaki et al. provides very
strong evidence that disruption of COMT/2-ME resulting in elevated
HIF-1a and subsequent sFlt-1 leadsto angiogenic dysfunction, placental
insufﬁciency and ultimately, the preeclamptic phenotype in mice.
Placental transport
Glucose transport is up-regulated by hypoxia in a number of cell types
and is crucial for fetoplacental growth. In term placental villous
explants, in vitro hypoxic exposure increases Glut1 and Glut3 mRNA
levels and signiﬁcantly increases glucose consumption (Esterman
et al., 1997). It was subsequently shown that hypoxic induction of
Glut1 mRNA and protein in human BeWo and rat Rcho-1 trophoblast
cell lines was a result of HIF-1a interacting with a consensus HRE site
in the Glut-1 promoter (Hayashi et al., 2004). Furthermore, in human
BeWo cells and ﬁrst trimester explants, hypoxic induction of GLUT1
and GLUT3 was inhibited by asHIF-1a, and culture in 3% oxygen was
shown to increase transepithelial glucose transport (Baumann et al.,
2007). Paradoxically, expression of placental GLUT1 is decreased in
pregnancies at high altitude (Zamudio et al., 2006).
The placental barrier is also a site of iron transport and recently
hypoxia and HIF have been implicated in this process. Iron in serum
is mainly transported by transferrin (Dunn et al., 2007) which interacts
with the transferrin receptor (TfR) and this complex is internalized by
receptor-mediated endocytosis, enabling iron to enter the cell. It has
been previously shown that transferrin is up-regulated in response to
hypoxia and this is mediated by HIF in hepatoma cells (Rolfs et al.,
1997). Similarly, culture of human Hep3B hepatoma cells increases
TfR mRNA expression via HIF-1 dependent mechanisms (Tacchini
et al., 1999). Surprisingly, expression of TfR is decreased in the placen-
tae of pregnancies at high altitude (Zamudio et al., 2006) and in preg-
nancies complicated by pre-eclampsia (Khatun et al., 2003). However,
there is currently no direct evidence for HIF regulation of tranferrin or
TfR in the placenta. There are very conﬂicting results between in vitro
and in vivo studies regarding the effect of hypoxia on GLUTs and TfR in
the placenta, perhaps, in part, because of the chronic exposure to
hypoxia in pregnancies at high altitude compared with the short-term
in vitro experiments. Additionally, other factors involved in the regu-
lation of these transporters in vivo may be missing from the in vitro
system, which may warrant further investigation.
The future of placental HIF
research
While oxygen regulation of placental development and function and
the role of HIFs in these processes is an area of keen interest, the
424 Pringle et al.currently available data are highly confusing. In vitro studies examining
the effects of oxygen are all diverse in methodology in terms of
media composition, cell line versus primary trophoblasts, ﬁrst trime-
ster versus term placental samples, presence or absence of ECM
substrate and timing of exposure. Most studies use 20% oxygen,
which is hyperoxic, as a control or comparison group and is irrele-
vant when considering the physiology of the placenta and all but a
few tissues for that matter: it is only useful in attempts to
compare it with previous observations in the literature. How then
can these data be truly interpreted and related to the in vivo situ-
ation? It is clear that what is needed is a systematic study looking
at the effects of low oxygen (1–3%) compared with physiological
control (5–10%) using placental villi from different gestational ages.
In addition, given that the effects of prolonged versus acute
hypoxia in the placenta are yet to be explored, it will be of great
interest to examine this in the future.
Secondly, publication of articles that only report HIF mRNA or
protein levels will no longer be sufﬁcient. Ideally, studies examining
the regulation of HIF should, where possible, include data on
mRNA, protein and DNA binding for both HIF-1 and HIF-2. It is
only when more data, such as these for placenta, are available that
we will be able to draw accurate conclusions about the role of HIFs
in placental biology. In addition, the regulation of HIFs is complex,
and involves factors inﬂuencing stability, degradation and transcrip-
tional activity of the HIFs. Investigation of other components of the
HIF regulatory network, such as asHIF-1a, may offer valuable insights
into placental HIF regulation in both normal and pathological pregnan-
cies. Finally, HIF can no longer be considered simply as a transcription
factor which is regulated by hypoxia. Future studies examining the
regulation of HIF by oxygen and other factors are essential if we are
to move forward in this ﬁeld.
Conclusion
The HIFs are able to function throughout all aspects of normal and
abnormal placental differentiation, growth and function; during the
ﬁrst trimester (physiologically low oxygen), during mid-late gestation
(where there is adequate maternal blood supply and placental oxy-
genation) and in pathological pregnancies complicated by placental
hypoxia/ischemia. The identity of HIFs as simply hypoxia-responsive
transcription factors is an oversimpliﬁcation and very misleading, as
they do much more. During normal pregnancy HIFs respond to
complex alterations in oxygen, hormones, cytokines and growth
factors to precisely regulate placental invasion, differentiation, trans-
port and vascularization. In the ever-changing environment created
during pregnancy, the HIFs appear to act as key mediators of pla-
cental development and function and thereby are likely to be
important contributors to both normal and adverse pregnancy
outcomes.
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